Abbott revenue falls short of estimates on weak demand for diagnostic devices

0
127

(Reuters) -Abbott missed analysts’ estimates for third-quarter revenue on Wednesday, as weakness in its diagnostics and nutritional businesses failed to offset strong demand for its medical devices, sending its shares down 3% premarket.

The company had flagged volatility in the businesses as it navigates a sharp decline in COVID-19 testing demand, new U.S. tariffs, and a freeze on foreign aid by President Donald Trump’s administration.

The decision to halt foreign aid has upended the supply chain for medical products and diagnostic tests crucial for fighting diseases including HIV and malaria in some of the world’s poorest countries.

Meanwhile, Abbott is also facing pricing pressure from China’s procurement program that buys medical devices in bulk at steep discounts.

Total revenue of $11.37 billion for the quarter ended September 30 slightly missed analysts’…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here